2020 - 2 Issue

Original article

Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma

Ján Lešták ORCID
Martin Fůs ORCID – Iveta Weissová – Klára Marešová ORCID

Full Text links

DOI: 10.31348/2020/17

Published in Czech and Slovak Ophtalmology: 2020 - 2

Published on website: 01.10.2020

Keywords: normotensive glaucoma, betaxolol, brimonidin and carteol treatment, pattern defect

Summary

Purpose: The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG).

Materials and methods: This study included (60 eyes of) 30 patients with NTG. First group consisted of 20 eyes of 10 patients of the average age of 58.5 years, who were treated by betaxolol. Second group also consisted of 20 eyes of 10 patients of the average age of 62.6 years and they were treated by brimonidine. Third group had the same count of the eyes and patients, the average age was 61.1 years and these patients were treated by carteolol. Diagnose of NTG was based on the comprehensive ophthalmological examination including electroretinography and visual evoked potentials. Visual fields were examined by fast threshold glaucoma test using Medmont M700 device. We compared pattern defect (PD) in the visual field for 3 years. The including criteria were: similar visual field findings at the beginning of the study, stable eye therapy (treatment was not changed during the study), uncorrected or best corrected (up to +-3 D) visual acuity of 1,0 of ETDRS, intraocular pressure between 10-15 mm Hg, if present, then compensated cardiovascular disease, no other internal or neurological disorders.

Results: We didn’t notice any statistically important difference of PD. The study revealed that brimonidin (p=0,99) and betaxolol (p = 0,81) had the best effect.

Conclusion: Local therapy of betaxolol, brimonidine and carteolol has an essential clinical value in normotensive glaucoma. All the mentioned treatments had a protective effect on the visual field. However, local side-effects of brimonidinu are a question.

References

  1. Adkins, JC., Balfour, JA.: Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging, 12; 1998:225–241.
  2. Brogiolo, G., Flammer, J., Haefliger, IO.: Latanoprost is a vaso - constrictor in isolated porcine ciliary arteries. Klin Monbl Augenheilkd. 218;2001:373–375.
  3. Collaborative Normal-Tension Glaucoma Study Group: Com - parison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol, 126;1998:487- 497.
  4. Flammer, J.: Glaukom. Triton 2003, ISBN 80-7254-351–2, 417 s.
  5. Gulati, V., Fan, S., Zhao, M. et al.: Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. Arch Ophthalmol, 130;2012: 677–684.
  6. Chen, MJ., Ching, J., Chou, K. et al.: Color Doppler imaging of re - trobulbar hemodynamics after topical carteolol in normal tension glaucoma. Zhonghua Yi Xue Zhi (Taipei), 64;2001:575–580.
  7. Kanski, JJ., Bowling, B., Nischal, K. et al.: 7th ed. Edinburgh: Else - vier Saunders; 2011. Clinical Ophthalmology: A Systematic Approach; 346–348 s.
  8. Kawase, K., Yamamoto, T., Muramatsu, T. et al.: Long-acting car - teolol hydrochloride 2% ophthalmic solution phase IV study - investigation of the effectiveness, safety and plasma concentration. Nippon Ganka Gakkai Zasshi. 114;2010:976–982.
  9. Krupin, T., Liebmannm JM., Greenfield, DS. et al.: Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: Results from the Low-Pres­ sure Glaucoma Treatment Study. Am J Ophthalmol, 151;2011: 671–681.
  10. Kuerten, D., Fuest, M., Bienert, M. et al.: Ocular hemodynamics in Acute Nonarteritic Anterior Ischemic Optic Neuropathy Compared with normal tension glaucoma. J Glaucoma, 28;2019:334–340.
  11. Lestak, J., Nutterova, E., Bartosova, L. et al.: The Visual Field in Normal Tension and Hyper Tension Glaucoma. IJSR, 3;2014:49–51.
  12. Liu, CJ., Ko,. YC., Cheng, CY., et al.: Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma. Br J Ophthalmol, 86;2002:1236–1239.
  13. Maeda, H., Tanaka Y., Yamamoto M. et al.: Effect of topical carte - olol on visual function in normal-tension glaucoma. Nippon Ganka Gakkai Zasshi, 101;1997:227–231.
  14. Maresova, K., Lestak, J., Fus M. et al.: Effect of prostaglandins and beta blockers on progression of hypertensive and normotensive glaucoma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.(in press)
  15. Mizuki, K., Yamazaki, Y.: Effect of Carteolol Hydrochloride on Ocular Blood Flow Dynamics in Normal Human Eyes. Nippon Ganka Gakkai Zasshi. 104;2000:226–231.
  16. Symes, R.J., Mikelberg, F.S.: Normal tension glaucoma manage - ment: a survey of contemporary practice. Can J Ophthalmol, 52; 2017:361–365.
  17. Tamaki, Y., Araie, M., Tomita, K. et al.: Effect of topical beta-bloc - kers on tissue blood flow in the human optic nerve head. Curr Eye Res, 16; 1997:1102–1110.
  18. Tepelus, TC., Song, S., Borrelli, E. et al.: Quantitative Analysis of Retinal and Choroidal Vascular Parameters in Patients With Low Tension Glaucoma. J Glaucoma, 28;2019:557–562.
  19. Vysniauskiene, I., Allemann, R., Flammer, J. et al.: Vasoactive re - sponses of U46619, PGF2alpha, latanoprost, and travoprost in isolated porcine ciliary arteries. Invest Ophthalmol Vis Sci, 47;2006: 295–298.
  20. Xu, S., Huang, S., Lin, Z. et al.: Color Doppler Imaging Analy - sis of Ocular Blood Flow Velocities in Normal Tension Glaucoma Patients: A Meta-Analysis. J Ophthalmol, 2015: 919610. doi: